# US 12,180,256 B2 · Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,256 B2
- Document ID: US12180256B2
- Status: Granted
- Kind: B2
- Application number: 17/351,341
- Filed: 2021-06-18
- Published: 2021-10-14
- Granted: 2024-12-31
- Earliest claimed: 2015-05-06
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Oliver Schoor; Andrea Mahr; Toni Weinschenk; Anita Wiebe; Jens Fritsche; Harpreet Singh
- Web page: https://patentgrep.com/patent/US12180256B2

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001148: {Regulators of development}
- A61K 39/001154: {Enzymes}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3076: {against structure-related tumour-associated moieties}
- C12N 5/0636: {T lymphocytes}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12N 2310/16: Aptamers
- C12N 2501/50: Cell markers; Cell surface determinants
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A peptide consisting of the amino acid sequence GLIDEVMVL (SEQ ID NO: 22) in the form of a pharmaceutically acceptable salt.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the pharmaceutically acceptable salt is chloride salt.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the pharmaceutically acceptable salt is acetate salt.

### Claim 4 (depends on 1)

A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the peptide is in the form of a chloride salt.

### Claim 6 (depends on 4)

The composition of claim 4, wherein the peptide is in the form of an acetate salt.

### Claim 7 (depends on 4)

The composition of claim 4, further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the adjuvant is IL-2.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the adjuvant is IL-7.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the adjuvant is IL-12.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the adjuvant is IL-15.

### Claim 12 (depends on 7)

The composition of claim 7, wherein the adjuvant is IL-21.

### Claim 13

A pegylated peptide consisting of the amino acid sequence of GLIDEVMVL (SEQ ID NO: 22) or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The peptide of claim 13, wherein the pharmaceutically acceptable salt is chloride salt.

### Claim 15 (depends on 13)

The peptide of claim 13, wherein the pharmaceutically acceptable salt is acetate salt.

### Claim 16 (depends on 13)

A composition comprising the pegylated peptide of claim 13 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A composition comprising the peptide of claim 1, wherein the composition is a pharmaceutical composition and comprises water and a buffer.

### Claim 18

A peptide consisting of the amino acid sequence GLIDEVMVL (SEQ ID NO: 22) in the form of a salt.

### Claim 19 (depends on 18)

The peptide of claim 18, wherein the salt is chloride salt.

### Claim 20 (depends on 18)

The peptide of claim 18, wherein the salt is acetate salt.